Search research articles
Contact Us
Filters
Showing results (31-40 of 35) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 35 results.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial
May Ee Png, Victoria Harris, Jenna Grabey, et al.
The Lancet. Infectious Diseases
|
September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial
Victoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
Nature Communications
|
February 23, 2024
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients
Joseph F Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
The New England Journal of Medicine
|
April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients
Christopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Lancet (London, England)
|
December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Christopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 35) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 35 results.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial
May Ee Png, Victoria Harris, Jenna Grabey, et al.
The Lancet. Infectious Diseases
|
September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial
Victoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
Nature Communications
|
February 23, 2024
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients
Joseph F Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
The New England Journal of Medicine
|
April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients
Christopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Lancet (London, England)
|
December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Christopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Page
of 4